{"organizations": [], "uuid": "c122cf623fb1523843151a822cbd87cb6b8d2ecb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/agios-sizes-up-funding-needs/agios-sizes-up-funding-needs-idUSL1N1PE14E", "country": "US", "domain_rank": 408, "title": "Agios sizes up funding needs", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-19T19:56:00.000+02:00", "replies_count": 0, "uuid": "c122cf623fb1523843151a822cbd87cb6b8d2ecb"}, "author": "", "url": "https://www.reuters.com/article/agios-sizes-up-funding-needs/agios-sizes-up-funding-needs-idUSL1N1PE14E", "ord_in_thread": 0, "title": "Agios sizes up funding needs", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "agios", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "cowen", "sentiment": "none"}, {"name": "ifr magazine", "sentiment": "none"}, {"name": "agios pharmaceuticals", "sentiment": "none"}, {"name": "jp morgan", "sentiment": "none"}, {"name": "goldman sachs", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 19 (IFR) - Agios Pharmaceuticals pivoted from industry conferences to the capital markets, securing US$425m in a follow-on stock sale that meets its funding needs for the year.\nJP Morgan, Goldman Sachs and Cowen marketed for one day Thursday before pricing 7.1m shares at US$67, 4.7% below pre-launch levels but marking a slight increase from the US$400m, fixed size targeted at launch.\nAgios shares traded at US$71.56 on Friday.\nAgios, which presented at the JP Morgan healthcare conference a week earlier, is using proceeds to support a recently launched cancer drug and another that is pending regulatory approval. (This story will appear in the January 20 issue of IFR Magazine)\n ", "external_links": [], "published": "2018-01-19T19:56:00.000+02:00", "crawled": "2018-01-19T20:09:31.023+02:00", "highlightTitle": ""}